Latanoprost / Timolol: 3 agencies, 2008–2021
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused latanoprost / timolol: all 6 decisive outcomes across 2 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 13.7 years separate the first record, 14 Jan 2008 at SMC (Scotland), from the most recent, 22 Sep 2021 at HAS (France).
SMC (Scotland) changed its position: recommended on 14 Jan 2008, restricted by 13 May 2019.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for latanoprost / timolol at all.
Nothing has been added since 2021; on this evidence the file is dormant.
3 distinct indication wordings are recorded for latanoprost / timolol by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess latanoprost / timolol, on 14 Jan 2008; AWMSG (Wales) did not open a file until 15 Mar 2019 — an unusually long tail of 11.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 9 dated records fall in 2019 alone.
2 of the 3 agencies here assessed latanoprost / timolol more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 3 of the 18 agencies here have assessed latanoprost / timolol.
The full ledger for latanoprost / timolol reads 5 recommended, 2 other, 1 restricted and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 22 Sep 2021 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 7 Apr 2021 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 9 Oct 2019 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| SMC (Scotland) | 13 May 2019 | Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostag… | accepted (restricted) | source |
| AWMSG (Wales) | 15 Mar 2019 | Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficien… | outside AWMSG criteria | source |
4 further decisions for latanoprost / timolol, across 2 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- latanoprost — same ATC class S01E — Ophthalmologicals
- bimatoprost — same ATC class S01E — Ophthalmologicals
- travoprost — same ATC class S01E — Ophthalmologicals
- dorzolamide / timolol — same ATC class S01E — Ophthalmologicals
- bimatoprost / timolol — same ATC class S01E — Ophthalmologicals
- latanoprost / netarsudil — same ATC class S01E — Ophthalmologicals
Coverage: 9 decisions for latanoprost / timolol from 3 agencies, 2008 to 2021. Data to 7 Sep 2026. ATC class S01E — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.